How much does a box of Axitinib targeted drug cost?

Axitinib (Axitinib) is an oral drug targeted for the treatment of advanced renal cell carcinoma (renal cell carcinoma, RCC). It is a member of the tyrosine kinase inhibitors (tyrosine kinase inhibitors, TKIs) family. It mainly inhibits specific tyrosine kinases in tumor cells to prevent the growth and spread of cancer cells.

Axitinib has been launched in China and has been included in medical insurance. Patients can purchase it domestically. The price of 5mg*28 tablets is about 5,000 to 6,000 yuan. For specific prices, please consult the local hospital pharmacy. There are original and generic axitinib drugs abroad. The original drug is Pfizer's original drug, and the price is about 6,000 yuan; the generic drugs are mainly Bangladeshi generics and Indian generics. The price of Bangladeshi generics in 5mg*60 tablets is more than 1,000 yuan, and the price of Indian generics is around a few hundred yuan. The ingredients of original drugs and generic drugs are basically the same.

The main mechanism of action of axitinib is through the inhibition of vascular endothelial growth factor receptor (VEGFR), as well as its effect on other related signaling pathways, such as PDGFR (platelet-derived growth factor receptor) and c-KIT. VEGFRPlays a key role in the process of angiogenesis, and malignant tumors such as renal cell carcinoma often promote angiogenesis to obtain more nutrients and oxygen to support their abnormal growth.

An important goal of the drug during treatment is to inhibit these receptors and reduce the tumor cells' need for blood supply, thus slowing the growth of cancer cells. Axitinib may also have an effect on the tumor microenvironment, reducing blood vessel density and blood supply to the tumor.

Axitinib is often used as a first-line treatment option, especially for patients with advanced renal cell carcinoma, especially those who cannot be treated with surgery. Clinical trials have shown that axitinib has significant efficacy in controlling disease progression, prolonging progression-free survival, and improving patient survival rates.